Search Bar & Filters
Found 1493 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety, tolerability, and early effects of 4D-710, an investigational gene therapy, in adults with cystic fibrosis CF lung disease who cannot use or tolerate existing CFTR modulator therapies. A sub-study also includes adults with advanced CF lung disease or frequent lung flare-ups who are currently on CFTR modulator therapy. This Phase 12 open-label trial aims to find appropriate dosing and assess potential benefits for these patient groups. Participants receive a single inhaled dose of 4D-710, which is a gene therapy designed to deliver a corrected version of the CFTR gene to lung cells. The study includes a dose exploration phase for those ineligible for modulator therapy, a dose expansion phase at selected doses, and a sub-study for participants on modulator therapy receiving various doses. Each participant undergoes one administration of the therapy during the trial. Throughout the study, participants are monitored for adverse events over a 60-month period. Evaluations include lung function tests, oxygen saturation measurements, and tracking of pulmonary exacerbations. Participants maintain their existing treatments if applicable, and researchers assess safety and early signs of effectiveness. The total study duration extends up to approximately nine years, including long-term observation after dosing.
Actively Recruiting
Researchers are evaluating the safety, radiation distribution, and initial diagnostic ability of a drug called 18FFPyQCP for PET imaging in patients with colorectal, gastric, pancreatic ductal adenocarcinoma, invasive lobular breast, and epithelial ovarian cancers. This open-label, single-group Phase 12 study aims to better understand how this drug works in imaging these types of cancer. Participants will receive an injection of 18FFPyQCP followed by PETCT scans to visualize fibroblast activation protein in tumors. The study includes two cohorts one focusing on radiation dosimetry over up to 360 minutes post-injection, and another assessing diagnostic performance with follow-up procedures up to 42 days after injection. Women of childbearing potential and men with partners must use effective contraception during the study. During the trial, participants will undergo imaging visits and safety monitoring for adverse events until 48 hours after injection. Researchers will collect and analyze images, radiation exposure data, and diagnostic accuracy. The total duration includes screening, imaging, follow-up assessments, and safety evaluations, extending up to 42 days post-injection for some participants.
Actively Recruiting
Researchers are evaluating the use of PET imaging with the radioligand 18FPI-2620 to detect tau protein buildup in people with Alzheimers disease and control subjects. This open-label, multi-center, pivotal Phase 3 study compares imaging results during life to brain tissue analysis after death to assess the accuracy and safety of this diagnostic method. Participants will receive an intravenous injection of 18FPI-2620 at a dose of 185 MBq 20%. This study is non-randomized and single-group, focusing on the imaging procedure itself without placebo or alternative treatments. The study will continue until autopsy and brain tissue analysis are completed, with an average follow-up period of about one year. During the study, participants will undergo PET scans using 18FPI-2620. Researchers will assess the scans ability to correctly identify tau pathology related to Alzheimers disease by comparing them to post-mortem brain tissue analysis. The study includes safety monitoring and evaluation of the agreement between different readers interpreting the scans. Overall participation lasts until the participants death and brain autopsy, expected on average around one year after the scan.
Actively Recruiting
This research aims to evaluate the use of an investigational imaging agent called 18FPT2385 in patients with renal cell carcinoma RCC, including clear cell RCC and those with Von Hippel-Lindau VHL syndrome. The study is designed to explore how well this imaging method can measure levels of a protein called hypoxia-inducible factor-2alpha HIF2b1 in tumors, which is important for understanding the disease. It is an open-label, non-therapeutic trial involving three patient groups with different disease presentations. Participants will receive an intravenous injection of 18FPT2385 followed by PETCT or PETMRI scans to observe the distribution and uptake of the tracer in tumors. The first group consists of patients scheduled for surgery, who will have imaging before nephrectomy, with results compared to tissue analysis after surgery. The second group includes patients with metastatic clear cell RCC, who will have imaging and a mandatory biopsy of metastatic sites. The third group involves patients with VHL syndrome and various tumors, who will undergo imaging and are encouraged, but not required, to have a biopsy. Some participants may have repeat imaging after initial dosimetry assessments. Throughout the study, patients will undergo multiple imaging sessions, including dynamic and whole-body scans at different time points after tracer injection to analyze tracer kinetics and distribution. Researchers will collect tissue samples for comparison with imaging findings, and participants will continue with standard or experimental treatments as advised by their doctors. The study aims to correlate imaging results with tissue levels of HIF2b1 over up to five years, monitoring safety and feasibility during the process.
Actively Recruiting
Researchers are evaluating whether NPI-001 can slow the progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. This clinical trial will also assess the safety of NPI-001 by comparing it to a placebo. The main goals are to determine if NPI-001 preserves photoreceptors and to monitor any medical problems participants may experience while taking the drug. Participants will take either NPI-001 or a placebo tablet orally twice a day for 24 months. The study follows a randomized, double-masked design with two groups one receiving the active drug N-acetyl cysteine amide 250 mg twice daily and the other receiving a placebo. Over the course of the study, participants will attend nine clinic visits for checkups and tests. During the trial, participants will undergo assessments including measuring the ellipsoid zone area to evaluate photoreceptor preservation. Researchers will monitor safety and efficacy throughout the 24 months of treatment. The study is sponsored by Nacuity Pharmaceuticals, Inc. and aims to provide detailed information about the effect of NPI-001 on vision preservation in this patient population.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tenapanor in adults with Chronic Idiopathic Constipation CIC. This study is a 26-week, multi-center, randomized, double-blind, placebo-controlled trial followed by a 4-week treatment-free safety follow-up period. It aims to compare three different doses of tenapanor with a placebo taken twice daily to assess their impact on constipation symptoms. The study includes a 2-week screening period to confirm eligibility, followed by a 26-week randomized treatment period where patients receive either 5 mg, 25 mg, or 50 mg of tenapanor twice daily, or a matching placebo. Patients record their constipation symptoms daily in an electronic diary. After the treatment period, there is a 4-week safety follow-up without treatment to monitor any adverse effects. Participants will have regular visits every 2 to 6 weeks for safety checks including medical assessments, vital signs, ECG, and lab tests. Their symptom diaries will be reviewed throughout the study. The main outcome measured is the durable complete spontaneous bowel movements response at 12 weeks. Secondary outcomes include changes in bowel movement frequency, stool consistency, and straining. The total study duration is approximately 32 weeks including all phases.
Actively Recruiting
Researchers are evaluating the use of delgocitinib cream applied twice daily to treat adults with mild to severe lichen sclerosus LS, focusing mainly on female participants since LS is more common in females. This Phase 3 trial is designed to assess the efficacy and safety of delgocitinib in comparison to a cream vehicle over a long period. The study includes two parts Part 1 enrolls females to determine the best dose, and Part 2 enrolls both males and females to further evaluate safety and efficacy. Participants will be assigned randomly to receive either delgocitinib cream at specified doses or a cream vehicle. Treatments are applied twice daily during an initial 12-week period followed by a continuation treatment period lasting 40 weeks. Various dosing regimens are used across groups, including delgocitinib cream alone, cream vehicle alone, or combinations transitioning between the two during the study. Male participants will be included in a substudy to evaluate delgocitinibs effects in men. During the trial, participants will attend clinic visits and undergo assessments including measurement of skin condition severity using the IGA-LS score, clinical lichen sclerosus score CLISSCO, and patient-reported scales for skin pain and itch. Quality of life related to vulvar symptoms will also be monitored. Safety is carefully tracked through adverse event reporting and laboratory tests throughout the study, which lasts from 55 to 60 weeks per participant. The primary outcome is the number of participants achieving a specific improvement in LS severity at week 12.
Actively Recruiting
Researchers are investigating new treatments for advanced renal cell carcinoma RCC, a type of kidney cancer. This study compares a standard targeted therapy called belzutifan with a combination of belzutifan and another targeted therapy, zanzalintinib. The goal is to find out if adding zanzalintinib helps people with advanced RCC live longer and without their cancer worsening compared to belzutifan alone. Participants will be randomly assigned to one of two groups. One group will take 120 mg of belzutifan orally plus 60 mg of zanzalintinib once daily for about 24 months. The other group will take 120 mg of belzutifan plus a placebo matching zanzalintinib once daily for the same period. Both treatments are given as tablets taken by mouth. During the study, participants will have regular evaluations to monitor their cancers status, side effects, and quality of life. Researchers will use specific measures such as progression-free survival PFS and overall survival OS over up to 50 months. Other assessments include tumor response, duration of response, adverse events, and changes in health questionnaires related to physical function and symptoms. Safety and treatment effects will be carefully tracked throughout the study.
Actively Recruiting
Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.
Actively Recruiting
Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.
1-10 of 1,493
1